Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on April 4, 2024. The report details a corporate action approved by the Board of Directors regarding the company's stock repurchase program.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only financial metrics disclosed relate to the stock repurchase program:
- Repurchase Authorization: Up to $1.0 million of common stock.
- Shares Repurchased (as of March 31, 2024): 315,462 shares.
- Total Cost of Repurchases (as of March 31, 2024): $566,803.
Material Changes
The Board of Directors approved an extension of the previously announced stock repurchase program. The program is now authorized to continue until April 30, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the specific event of the program extension.
Key Facts for Investor Verification
- Verify the remaining authorization amount under the repurchase program ($1.0 million total cap minus $566,803 spent).
- Confirm the final date for repurchases is April 30, 2024.
- Note that this filing does not contain updated financial performance metrics for the period.